BG Klinikum Unfallkrankenhaus Berlin gGmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At BG Klinikum Unfallkrankenhaus Berlin gGmbH, clinical research in cardiovascular diseases focuses on improving care for people with acute myocardial infarction and pulmonary hypertension. These studies are designed to evaluate new treatment options that may reduce major heart-related events and help patients manage serious circulation and heart-lung conditions more effectively.
- Studying type 1 AMI to assess whether a new anti-inflammatory approach can lower the risk of major cardiovascular events
- Investigating pulmonary arterial hypertension to see if inhaled therapy can improve blood vessel function in the lungs
- Evaluating PH-HFpEF with the goal of improving exercise capacity and treatment tolerability
This work reflects a strong interest in therapies that target both symptom relief and longer-term outcomes in complex heart and lung-related disease.
Otorhinolaryngologic Diseases
Research in otorhinolaryngologic diseases at this Berlin hospital includes studies for idiopathic sudden sensorineural hearing loss. The main aim is to test whether a new treatment can improve hearing recovery compared with standard steroid-based care, supporting faster and more effective intervention for patients with sudden loss of hearing.
- Focusing on idiopathic sudden sensorineural hearing loss and the chance to restore hearing more effectively
- Comparing a novel therapy with established treatment to better understand hearing improvement
This area highlights efforts to find better options for an urgent condition where early treatment can make a meaningful difference.
Respiratory Tract Diseases
Clinical trials in respiratory tract diseases are examining treatments for pulmonary arterial hypertension and PH-HFpEF. The research is centered on improving breathing-related symptoms, exercise ability, and vascular health in patients with serious cardiopulmonary disease.
- Assessing a treatment for pulmonary arterial hypertension by measuring its effect on lung blood vessel resistance
- Testing therapy for PH-HFpEF to improve walking distance and daily physical function
These studies aim to clarify how new therapies may support patients whose lung and heart conditions limit everyday activity.
Skin and Connective Tissue Diseases
The skin and connective tissue diseases research portfolio includes work on deep partial and full-thickness burns. At the site, investigators are evaluating a new wound treatment intended to support closure of burn injuries and reduce scarring, with the goal of improving healing and recovery after severe skin damage.
- Studying deep partial and full-thickness burns to determine whether a new skin repair approach can improve wound closure
- Exploring ways to reduce scarring and support better recovery after major burn injury
This research area emphasizes advanced wound care and tissue healing in patients with complex injuries.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Apurano Pharmaceuticals GmbH4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in BG Klinikum Unfallkrankenhaus Berlin gGmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF | Tenax Therapeutics Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.